Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (371)	1/6/2000 9:09:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Isn't this promotion indication that they are moving forward or that cytokine partner is closing in? Did you miss this: <<..an antagonist for vascular endothelial growth factor (VEGF) for cancer, and second generation AXOKINE® ciliary neurotrophic factor for obesity.>> Sec. gen. Axokine? Is this reason that P&G give up right on Axokine so quickly? Miljenko

To: scaram(o)uche who wrote (371)	1/26/2000 8:40:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

More clues found to molecule's role in asthma 7:46 p.m. ET (053 GMT) January 25, 2000 WASHINGTON, Jan 25 ? A new study has found additional evidence that a chemical involved in inflammation may play a role in asthma, researchers said on Tuesday. The study found more of the chemical, known as interleukin-9 (IL-9), in tissue taken from the lungs of people with asthma than in tissue from healthy lungs, they said. Writing in the Journal of Allergy and Clinical Immunology, the team at McGill University in Montreal, Canada, and the Institut Pasteur in Lille, France, said they believed drugs that cancel out the effects of IL-9 might work to help treat asthma. "Based on these results, the previous genetic mapping studies and the biology of IL-9, it is our view that an antibody to IL-9 has significant promise as a therapy for asthma,' Dr. Qutayba Hamid, a professor of medicine at McGill who led the study, said in a statement. The results were released by Magainin Pharmaceuticals, which is developing IL-9 antibodies as an asthma treatment, along with Genentech Inc. Asthma affects nearly 15 million people in the United States, including about 5 million children. Interleukins have long been known to play a role in regulating the immune system and, in particular, to be responsible for causing the early stages of the inflammation in the lungs that leads to asthma attacks. They belong to a family of signalling chemicals known as chemokines. Chemokines are especially common in the immune system, where they can provoke inflammation. Other researchers have found a role for related chemokines, such as IL-4 and IL-13, in asthma. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx So, Mr. Schleifed, if Company have IL-4/13 combination trap (about 50X more potent than current antibody) it shouldn't be difficult to find 50:50 partner. Don't let me down now! Miljenko